文献速递肾移植肾血管病与高血压

氯噻酮与氨氯地平治疗接受他克莫司治疗的肾移植受者高血压:一项随机交叉试验

Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial.
PubMed 文献 · Am J Kidney Dis · 2017-03-01

在服用他克莫司的高血压肾移植受者中开展的随机非劣效交叉试验显示,氯噻酮与氨氯地平降压效果相当,但氯噻酮降低蛋白尿30%并减少外周水肿,同时短暂降低肾功能并升高血尿酸和糖化血红蛋白。

要点

  • 氯噻酮与氨氯地平降压效果相当,效应量为-4.2 mmHg(95%CI -7.3至1.1)。
  • 氯噻酮降低蛋白尿30%(效应量-65 mg/g,95%CI -108至-35)。
  • 氯噻酮减少医生评估的外周水肿(22%至10%,P<0.05)。

核心结论

  • 氯噻酮是肾移植后与氨氯地平降压效果相当的抗高血压药物。

研究设计与样本

  • 随机非劣效交叉试验,非劣效界值为-2.8 mmHg。
  • 纳入88例接受他克莫司的高血压肾移植受者中49例(56%)日间平均收缩压>140 mmHg者,41例完成研究。

主要发现

  • 氨氯地平和氯噻酮治疗8周均降低动态收缩压,氨氯地平组从150±12降至137±12 mmHg,氯噻酮组从151±12降至141±13 mmHg,效应量为-4.2 mmHg(95%CI -7.3至1.1)。
  • 氯噻酮降低蛋白尿30%(效应量-65 mg/g,95%CI -108至-35)。
  • 氯噻酮减少医生评估的外周水肿(22%至10%,P<0.05)。
  • 氯噻酮短暂降低肾功能并升高血尿酸和糖化血红蛋白水平。

局限性

  • 开放标签设计。
  • 随访时间短。
  • 符合方案分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chlorthalidone is a very effective antihypertensive drug, but it has not been studied prospectively in kidney transplant recipients with hypertension. Recent data indicate that calcineurin inhibitors activate the thiazide-sensitive sodium chloride cotransporter, providing further rationale to test thiazides in this population. STUDY DESIGN: Randomized noninferiority crossover trial (noninferiority margin, -2.8mmHg). SETTING & PARTICIPANTS: Hypertensive kidney transplant recipients using tacrolimus (median duration, 2.4 years after transplantation; mean estimated glomerular filtration rate, 63±27 [SD] mL/min/1.73m2; mean systolic blood pressure [SBP], 151±12mmHg). INTERVENTION: Amlodipine (5-10mg) and chlorthalidone (12.5-25mg) for 8 weeks (separated by 2-week washout). OUTCOMES: Average daytime (9 am to 9 pm) ambulatory SBP. MEASUREMENTS: Blood pressure and laboratory parameters. RESULTS: 88 patients underwent ambulatory blood pressure monitoring, of whom 49 (56%) with average daytime SBP>140mmHg were enrolled. 41 patients completed the study. Amlodipine and chlorthalidone both reduced ambulatory SBP after 8 weeks (mean changes of 150±12 to 137±12 [SD] vs 151±12 to 141±13mmHg; effect size, -4.2 [95% CI, -7.3 to 1.1] mmHg). Despite these similar blood pressure responses, chlorthalidone reduced proteinuria by 30% (effect size, -65 [95% CI, -108 to -35] mg/g) and also reduced physician-assessed peripheral edema (22% to 10%; P<0.05 for both). In contrast, chlorthalidone temporarily reduced kidney function and increased both serum uric acid and glycated hemoglobin levels. LIMITATIONS: Open-label design, short follow-up, per-protocol analysis. CONCLUSIONS: Chlorthalidone is an antihypertensive drug equally effective as amlodipine after kidney transplantation.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Moes AD, Hesselink DA, van den Meiracker AH, et al. Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial. Am J Kidney Dis. 2017. PMID: 28259499. doi:10.1053/j.ajkd.2016.12.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。